Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

As psychedelic medicine inches closer to mainstream acceptance, researchers have tackled a crucial question: How many ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

According to Rab, psilocybin-assisted treatment currently has a breakthrough designation with the FDA, meaning that it will ...

Psychedelic-assisted therapy is a combined method that uses psychotherapy and pharmacotherapy with the help of psychedelics ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental ...

Trippy: The Peril and Promise of Medicinal Psychedelics” looks at both the Indigenous use and modern research behind psychoactive substances.

'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Althea, a Boulder-based company, has created software they hope will become the de facto system for providers of ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...